Unlock stock picks and a broker-level newsfeed that powers Wall Street. Upgrade Now
US Penny Stocks: 3 Picks With Market Caps Over $60M

In This Article:

As major U.S. stock indexes face potential weekly losses following a disappointing jobs report and declining consumer sentiment, investors are exploring diverse opportunities across the market spectrum. Penny stocks, often associated with smaller or newer companies, continue to present intriguing possibilities for those seeking growth at lower price points. Despite being considered a throwback term, these stocks can offer significant potential when backed by strong financials and solid fundamentals.

Top 10 Penny Stocks In The United States

Name

Share Price

Market Cap

Financial Health Rating

BAB (OTCPK:BABB)

$0.88

$6.38M

★★★★★★

QuantaSing Group (NasdaqGM:QSG)

$3.08

$120.63M

★★★★★★

ZTEST Electronics (OTCPK:ZTST.F)

$0.2798

$10.12M

★★★★★★

Imperial Petroleum (NasdaqCM:IMPP)

$2.99

$90.69M

★★★★★★

North European Oil Royalty Trust (NYSE:NRT)

$4.82

$45.59M

★★★★★★

Golden Growers Cooperative (OTCPK:GGRO.U)

$4.50

$67.38M

★★★★★★

BTCS (NasdaqCM:BTCS)

$2.95

$53.09M

★★★★★★

Smith Micro Software (NasdaqCM:SMSI)

$1.52

$26.96M

★★★★★☆

CBAK Energy Technology (NasdaqCM:CBAT)

$0.882

$81.84M

★★★★★☆

Safe Bulkers (NYSE:SB)

$3.61

$396.15M

★★★★☆☆

Click here to see the full list of 706 stocks from our US Penny Stocks screener.

Here we highlight a subset of our preferred stocks from the screener.

Entera Bio

Simply Wall St Financial Health Rating: ★★★★☆☆

Overview: Entera Bio Ltd. is a clinical-stage company developing oral peptide or protein replacement therapies for unmet medical needs, with a market cap of $88.40 million.

Operations: Currently, there are no reported revenue segments for this clinical-stage company focused on developing oral peptide or protein replacement therapies.

Market Cap: $88.4M

Entera Bio Ltd., a clinical-stage biotech company, is pre-revenue with less than US$1 million in sales, highlighting its early-stage nature. The company's financial position reveals less than a year of cash runway and no debt, which can be advantageous but also indicates potential liquidity challenges. Despite being unprofitable and not expected to achieve profitability in the next three years, Entera has managed to reduce losses over the past five years by 2.8% annually. Its experienced management and board provide some stability amid high share price volatility and significant net losses reported recently.

NasdaqCM:ENTX Financial Position Analysis as at Feb 2025
NasdaqCM:ENTX Financial Position Analysis as at Feb 2025

GrowGeneration

Simply Wall St Financial Health Rating: ★★★★★★

Overview: GrowGeneration Corp. operates retail hydroponic and organic gardening stores across the United States with a market cap of $82.35 million.